Symptom rating scale for assessing hyperthyroidism.
A hyperthyroid symptom scale (HSS) was designed and administered to ten subjects with untreated Graves' disease. All subjects had clinical and chemical evidence of hyperthyroidism and reproducible HSS scores of 20 or more points. During sequential treatments with propranolol hydrochloride (phase 2) followed by propylthiouracil (phase 3) there was a significant decline in the HSS scores at each phase. Accompanying the decrease in HSS scores was a decrease in heart rate, but there was no change in thyroid function test results at phase 2 and a decrease in heart rate, thyroid function test results, and goiter size at phase 3. This new scale includes ten categories of symptoms, it is sensitive to changes in both the adrenergic and metabolic components of hyperthyroidism, and it is useful in the clinical assessment and management of patients with thyrotoxicosis.
D000328:Adult; D000704:Analysis of Variance; D002986:Clinical Trials as Topic; D003953:Diagnosis-Related Groups; D005069:Evaluation Studies as Topic; D005260:Female; D006111:Graves Disease / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000627:therapeutic use; D011441:Propylthiouracil / Q000627:therapeutic use; D012720:Severity of Illness Index
D011441:Propylthiouracil; D011433:Propranolol